Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Gains from Sales and Divestitures (2023 - 2025)

Core Laboratories filings provide 3 years of Gains from Sales and Divestitures readings, the most recent being $463244.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 80.44% to $463244.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $463244.0, a 80.44% increase, with the full-year FY2025 number at $463244.0, up 80.44% from a year prior.
  • Gains from Sales and Divestitures hit $463244.0 in Q4 2025 for Core Laboratories, up from $256724.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $463244.0 in Q4 2025 to a low of $256724.0 in Q4 2024.
  • Median Gains from Sales and Divestitures over the past 3 years was $336844.0 (2023), compared with a mean of $352270.7.
  • Biggest five-year swings in Gains from Sales and Divestitures: decreased 23.79% in 2024 and later surged 80.44% in 2025.
  • Core Laboratories' Gains from Sales and Divestitures stood at $336844.0 in 2023, then decreased by 23.79% to $256724.0 in 2024, then surged by 80.44% to $463244.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $463244.0 (Q4 2025), $256724.0 (Q4 2024), and $336844.0 (Q4 2023) per Business Quant data.